Actionable news
All posts from Actionable news
Actionable news in EGLT: EGALET CORPORATION,

EGLT Gets FDA Panel Nod, NXTM On A High, BDSI Ahead Of Schedule

Shutterstock photo

( - Shares of Aquinox Pharmaceuticals Inc. (

) were down over 14% in extended trading on Thursday, following wider-than-expected loss in the second quarter ending June 30, 2016.

The net loss for the second quarter of 2016 widened to $10.9 million or $0.63 per share from $4.8 million or $0.44 per share in the second quarter of 2015. Analysts polled by Thomson Reuters expected the company to report a loss of $0.41 per share.

The company attributed the wider loss to increased operating expenditures related to the initiation of its LEADERSHIP 301 clinical trial.

AQXP closed Thursday's trading at $9.61, up 7.13%. In after hours, the stock was down 14.67% to $8.20.

Arbutus Biopharma Corp. (

) has a couple of catalysts lined up for the coming months.

The company is on track to report single dose HBsAg reduction data from a phase II trial of ARB-1467 in HBV-infected patients in the third quarter, and HBsAg reduction data from the multiple dose portion of the phase II trial testing ARB-1467 in HBV-infected patients in the fourth quarter of this year.

ABUS closed Thursday's trading at $4.37, down 0.68%.

BioDelivery Sciences International Inc. (

) now expects to report topline results from its phase 2b study of Clonidine Topical Gel in the treatment of pain associated with painful diabetic...